ANI Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ANI Pharmaceuticals, Inc.
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Rocket Pharmaceuticals’ CEO Talks Gene Platforms and Spiritual Leadership
The trajectory of Rocket Pharmaceuticals, a clinical-stage gene therapy company, has been marked by a series of impressive milestones. At least partial credit for those accomplishments goes to CEO Gaurav Shah, who co-founded the company in 2015 and has combined scientific, business and managerial savvy to progress the company through two regulatory filings this year. Shah recently spoke to In Vivo about the company and his own leadership style.
- Contract Research Organization-CRO
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- BioSante Pharmaceuticals, Inc.
- Cell Genesys, Inc.
- Novitium Pharma LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.